Business Context and Reporting Period
Company: CEA Industries Inc. (Nasdaq: BNC)
Filing Type: Form 8-K (Current Report)
Date of Report: December 26, 2025
Event: Adoption of a Stockholder Rights Agreement (Poison Pill) and designation of Series C Junior Participating Preferred Stock.
Key Financial Metrics
This filing is a current report regarding corporate governance and defensive measures. It does not contain financial statements, revenue, profit, cash flow, or debt metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Corporate Actions
- Adoption of Rights Plan: On December 26, 2025, the Board adopted a stockholder rights agreement declaring a dividend of one Right for each outstanding share of Common Stock and for shares underlying certain warrants.
- Trigger Threshold: Rights become exercisable if any person or group acquires 15% or more of the outstanding Common Stock (an "Acquiring Person").
- Flip-In Mechanism: Upon a "Flip-in Event," holders (excluding the Acquiring Person) may purchase Common Stock with a value equal to two times the exercise price ($33.50 per Right).
- Flip-Over Mechanism: In the event of a merger or asset sale following a Stock Acquisition Date, Rights may be exchanged for stock of the acquiring company with a value equal to two times the exercise price.
- Preferred Stock Designation: The Board approved a Certificate of Designation for 200,000 shares of Series C Junior Participating Preferred Stock, which serves as the underlying security for the Rights.
- Context of Adoption: The plan was adopted in response to the formation of the "YZi Labs Group" by YZi Labs Management Ltd., which filed a Schedule 13D reporting a 7.0% stake and seeking control of the Board. The group holds warrants that could increase its ownership to approximately 34.2% on a diluted basis.
Guidance, Outlook, and Risks
- Management Commentary: The Board stated the Rights Agreement is not intended to prevent YZi Labs from soliciting stockholders or prevent stockholders from granting revocable consents. It is also not expected to interfere with mergers approved by the Board.
- Expiration: The Rights will expire on the earliest of: December 26, 2026; redemption by the Company; exchange by the Company; or the closing of a Board-approved merger.
- Redemption: The Board may redeem the Rights at $0.001 per Right at any time prior to a person becoming an Acquiring Person.
- Risks: The primary risk addressed is an unsolicited takeover attempt or accumulation of shares by a single entity exceeding 15% without Board approval. The plan dilutes the economic interest of any Acquiring Person while preserving value for other shareholders.
Investor Verification Checklist
- Verify the current trading price of Common Stock (BNC) relative to the $33.50 exercise price to assess immediate dilution impact.
- Review the full text of the Stockholder Rights Agreement (Exhibit 4.1) for specific exceptions to the 15% threshold.
- Monitor the status of the YZi Labs Group's consent solicitation and their potential exercise of warrants.
- Confirm the Record Date of January 8, 2026, for eligibility to receive the Rights dividend.
- Check for any subsequent filings regarding the redemption or amendment of the Rights Agreement.